Developing a Treatment for Select Cardiopulmonary Diseases using INOpulse, a Portable Drug/Device Combination Delivering Pulse Nitric Oxide; Report Available here: http://www.lifescicapital.com/equity-research/bellerophon/
NEW YORK, NY / ACCESSWIRE / February 23, 2017 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of Bellerophon (NASDAQ: BLPH), a biotherapeutics company focused on the development of inhaled nitric oxide (NO) therapy for patients with cardiopulmonary diseases. The company is developing a portable drug/device called INOpulse to deliver pulsed pharmaceutical grade NO to vasodilate the pulmonary artery. The NO is delivered through a patented triple lumen cannula that is compatible with oxygen therapy.
The Company completed a randomized Phase II study to evaluate the INOpulse in PAH patients. The study found a statistically significant increase in 6 minute walk distance (6MWD) in patients receiving a high dose of NO and who were also on long-term oxygen therapy (LTOT). In addition to an increase in 6MWD within this patient population, there was a significant increase in 6MD in INOpulse and LTOT treated patients that used the therapy for more than 12 hours per day. The trial identified a target dose for INOpulse and patient population most likely to benefit from therapy.
INOpulse is being evaluated in the first of two Phase III trials to evaluate the benefit of INOpulse in pulmonary arterial hypertension (PAH) patients on long term oxygen therapy (LTOT), and expects to report interim results in late 2017. The second study employs an innovative withdrawal design that will allow Bellerophon to reach an NDA, and potential marketing approval for INOpulse, two years earlier than expected and with dramatically reduced costs. Results for this trial are expected in the first half of 2018.
In addition to its evaluation of INOpulse for PAH, Bellerophon is clinically evaluating INOpulse for pulmonary hypertension-chronic obstructive pulmonary disease (PH-COPD) and pulmonary hypertension- associated with idiopathic pulmonary fibrosis (PH-IPF), both are indications with no approved therapies. Bellerophon is separately evaluating the efficacy of INOpulse in a Phase II study for PH-COPD and a Phase II patients for PH-IFP in a Phase II study and expects topline data during the first half of 2017.
In a 42 page Initiation Report LifeSci Capital explains the preclinical and clinical data supporting INOpulse in PAH, PH-COPD, and PH-IPF. We outline the market opportunity for each indication and discuss the landscape of approved agents and those in development.
Dr. Isaacson's full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on BioInvent as developments occur.
The LifeSci Capital research team is led by Dr. Jerry Isaacson, an industry veteran with broad experience in biotechnology, having worked in both public and private biotech companies in areas ranging from medicinal chemistry and analytical chemistry to patents and investor/public relations. Dr. Isaacson holds a Bachelor of Arts degree in Chemistry from Harvard University and received his Ph.D. in Organic Chemistry from the University of California in San Diego.
About LifeSci Capital:
LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients' businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company's website, www.lifescicapital.com.
Analyst Contact:
Jerry Isaacson, Ph.D.
Phone: (646) 597-6991
Email: [email protected]
SOURCE: LifeSci Capital, LLC